World's Best Scientists 2026 revealed!
Stephen D. Gillies

Stephen D. Gillies

D-Index & Metrics

Immunology

D-Index
73
Citations
15875
World Ranking
2159
National Ranking
1049

Stephen D. Gillies publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Stephen D. Gillies sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 135 publications — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Stephen D. Gillies D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Stephen D. Gillies sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 73 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Stephen D. Gillies is affiliated with MSD in the United States and has contributed extensively to research primarily within the field of Medicine. Their work spans multiple specialized subfields including Oncology, Neurology, Immunology, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The scientist's research focuses on several key topics, among which are:

  • Neuroblastoma Research and Treatments
  • CAR-T cell therapy research
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Cancer therapeutics and mechanisms
  • Alzheimer's disease research and treatments

Notable recent publications by Stephen D. Gillies include:

  • Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation (2020), published in Scientific Reports
  • Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma (2022), published in Theranostics
  • In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response (2020), published in Frontiers in Immunology
  • Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma (2022), published in Journal for ImmunoTherapy of Cancer
  • Short-course neoadjuvant in situ vaccination for murine melanoma (2022), published in Journal for ImmunoTherapy of Cancer

Most frequent co-authors collaborating with Stephen D. Gillies are:

  • Paul M. Sondel
  • Amy K. Erbe
  • Alexander L. Rakhmilevich
  • Zachary S. Morris
  • Taylor Aiken

The scientist regularly publishes in venues such as:

  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Scientific Reports
  • Theranostics
  • Frontiers in Immunology

Stephen D. Gillies' contributions across these journals illustrate a focus on immunotherapy, cancer biology, and neurodegenerative disease research. The combination of topics and multidisciplinary subfields represents an intersectional approach involving immunological mechanisms, clinical oncology, and neurology.

Best Publications

  • Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

    Leonard D. Shultz;Bonnie L. Lyons;Lisa M. Burzenski;Bruce Gott

  • Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis

    Karen S. Moulton;Khashayar Vakili;David Zurakowski;Mohsin Soliman

  • High-level expression of chimeric antibodies using adapted cDNA variable region cassettes.

    Stephen D. Gillies;Kin-Ming Lo;John Wesolowski

  • Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

    S D Gillies;E B Reilly;K M Lo;R A Reisfeld

  • Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

    A L Yu;M M Uttenreuther-Fischer;C S Huang;C C Tsui

  • A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

    R. Handgretinger;K. Anderson;P. Lang;R. Dopfer

  • Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

    B M Mueller;C A Romerdahl;S D Gillies;R A Reisfeld

  • Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

    Suzanne S. Shusterman;Wendy B. London;Stephen D. Gillies;Jacquelyn A. Hank

  • Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy

    Holger N. Lode;Rong Xiang;Torsten Dreier;Nissi M. Varki

  • Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow

    Holger N. Lode;Rong Xiang;Nissi M. Varki;Carrie S. Dolman

  • Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

    Mayumi Naramura;Stephen D. Gillies;John Mendelsohn;Ralph A. Reisfeld

  • T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.

    J C Becker;J D Pancook;S D Gillies;K Furukawa

  • A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

    Kaci L. Osenga;Jacquelyn A. Hank;Mark R. Albertini;Jacek Gan

  • Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

    Holger N. Lode;Thomas Moehler;Rong Xiang;Alfred Jonczyk

  • Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

    David M. King;Mark R. Albertini;Heidi Schalch;Jacquelyn A. Hank

  • Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.

    Stephen D. Gillies;John S. Wesolowski

  • NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

    Ruth Esser;Tina Müller;Dörthe Stefes;Stephan Kloess

  • A Dual-Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-Mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice

    Rong Xiang;F. James Primus;J. Michael Ruehlmann;Andreas G. Niethammer

  • Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

    Mansoor N. Saleh;M.B. Khazaeli;M.B. Khazaeli;Richard H. Wheeler;Laquetta Allen

  • Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

    David C. Delgado;Jacquelyn A. Hank;Jill Kolesar;David Lorentzen

  • Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2rγnull Mice Engrafted with Mobilized Human Hematopoietic Stem Cells.

    Leonard Shultz;Bonnie L. Lyons;Lisa M. Burzenski;Bruce Gott

Frequent Co-Authors

Ralph A. Reisfeld
Ralph A. Reisfeld Scripps Research Institute
Jacquelyn A. Hank
Jacquelyn A. Hank University of Wisconsin–Madison
Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Rong Xiang
Rong Xiang Nankai University
David A. Cheresh
David A. Cheresh University of California, San Diego
Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Barbara M. Mueller
Barbara M. Mueller Torrey Pines Institute For Molecular Studies
Rupert Handgretinger
Rupert Handgretinger University of Tübingen
Jürgen C. Becker
Jürgen C. Becker University of Duisburg-Essen
Alice L. Yu
Alice L. Yu University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise in Immunology, several online degree options can open new career pathways in healthcare. One popular route is transitioning to advanced nursing roles, such as through an fnp to acnp bridge program online, which prepares family nurse practitioners to specialize in acute care settings.

Accelerated programs also offer a fast track to becoming a nurse practitioner. The accelerated np programs enable students with prior degrees to complete their nursing education efficiently while focusing on advanced practice skills critical in immunology-related fields.

For individuals without a nursing background, enrolling in online rn programs for non nurses provides a foundational pathway into nursing and healthcare, which can later lead to specialized immunology roles or advanced degrees.

Finally, understanding career prospects and compensation is vital. Exploring data on how much does a dnp make helps students plan their education and career pathway effectively, considering the return on investment in nursing and immunology-related careers.

Best Scientists Citing Stephen D. Gillies

Trending Scientists

Recently Published Articles